Abstract:Object:Lymphoplasmacytic lymphoma/ Waldenström's macroglobulinemia (LPL/WM) is a rare B-cell proliferative malignancy characterized by immunoglobulin M monoclonal gammopathy and /or bone marrow infiltration by lymphoplasmacytic cells. Recently, there are no large-scale studies to detect the clinical features, genetic background in patients with LPL/WM in China even Asia. The aim of this study is to explore the clinical and genetic differences, observe the impact of cytogenetic abnormalities on survival and prognosis in Chinese patients. Methods:305 patients with LPL/WM admitted in our hospital from June 1998 to December 2018 were retrospectively analyzed. Baseline characteristics, laboratory detection and therapy were compared using Chi-square test and Kaplan-Meier methodology was undertaken for survival analysis. Results:The median age of 305 patients in the study was 62 years (range 32-87) and male to female ratio was 2.45:1(216/89). The most common symptoms at diagnosis were fatigue (64.9%) and bleeding (14.1%).The patients in low, intermediate and high risk group of the international prognostic scoring system for WM (ISSWM) was 17.6%, 36.5% and 45.9%,respectively.The median hemoglobin was 8.5g/dl(range 2.4-18.7). About 41.3% patients had IgM higher than 4000mg/dl. The cytogenetic abnormalities were uncommon in LPL/WM patients. The chromosomal karyotypes were successful in 194 cases, of which 20 patients showed clonal abnormalities. 12 patients had two or more chromosome abnormalities. The most common chromosome abnormalities were deletion 6/6q(25%) and Y chromosome loss (20%). The median progression-free survival (PFS) and overall survival (OS) in patients with normal and abnormal chromosome karyotypes were similar. 194 patients had FISH detection, of which 33 patients (17%) had FISH abnormalities, 9 (4.6%) patients had two kind of abnormalities. The patients with more than one cytogenetic abnormality had lower survival than just had one abnormality or normal patients. The most common aberrations were 6q deletion and trisomy 12. 17p deletion was detected in 11 patients (11/184,6.0%) and it was a poor prognostic marker of PFS and OS. Single 13q14 deletion had not impact on PFS or OS, but when companied with other cytogenetic aberration, it could worsen the PFS and OS . Besides related to survival, cytogenetic abnormal was also related to the clinical features. Conclusions:Despite the low incidence and abnormal cytogenetic detection rate of LPL/WM, the clinical and genetic features are unique in Chinese patients. The cytogenetic aberrations play an important role in predicting prognosis. Disclosures No relevant conflicts of interest to declare.

Clonally related transformation from Waldenström macroglobulinemia to diffuse large B-cell lymphoma with central nervous system involvement at diagnosis: a case report and literature review

Multiple Myeloma with Isolated Central Nervous System Relapse after Autologous Stem Cell Transplantation: A Case Report and Review of the Literature

Diffuse large B-cell lymphoma with continuously elevated immunoglobulin M following treatment: a case report with pathologic, immunophenotypic, and molecular analyses

Diagnosis and Risk Stratification in Waldenström Macroglobulinemia

Coexistence of Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia, and Untreated Lymphoplasmacytic Lymphoma/waldenström Macroglobulinemia in a Same Patient: A Case Report.

Circulating tumor cells in Waldenström macroglobulinemia

Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors

Treatment and Outcome Patterns of Patients with Waldenström’s Macroglobulinemia: a Large, Multicenter Retrospective Review in China

Transformed Waldenström Macroglobulinemia Responsive to Tafasitamab Plus Lenalidomide: A Case Report

Waldenstrom’s Macroglobulinemia Associated with Hodgkin’s Lymphoma: a Case Report

Waldenström macroglobulinemia: a challenging case treated with anti-CD19 CAR-T cell therapy

Clinical analysis of 15 patients with Waldenstrom's macroglobulinemia

[Lymphoplasmacytic Lymphoma with Waldenström's Macroglobulinemia: a Clinicopathological and Immunophenotypic Study of 40 Chinese Patients].

Morphology, immunophenotypes, cytogenetics and molecular biology of Waldenstrom macroglobulinemia

Case report: Waldenstrom macroglobulinemia with systemic amyloidosis as the main manifestation

CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience

Current approach to Waldenström Macroglobulinemia

A rare case report of waldenström macroglobulinemia converted to serum low IgM

Targeting the Bone Marrow in Waldenstrom Macroglobulinemia

The Cytogenetic Aberrations of Lymphoplasmacytic Lymphoma/ Waldenström's Macroglobulinemia in China

[Evaluation of Clinical Characteristics, MYD88(L265P) Mutation, CXCR4(WHIM) Mutation and Prognosis in Waldenström Macroglobulinemia: A Single Center Retrospective Study of 93 Patients].